GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (FRA:H5P) » Definitions » Sale Of Investment

Hikma Pharmaceuticals (FRA:H5P) Sale Of Investment : €1 Mil (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Hikma Pharmaceuticals Sale Of Investment?

Hikma Pharmaceuticals's sale of investment for the six months ended in Dec. 2023 was €0 Mil. It means Hikma Pharmaceuticals gained €0 Mil from selling investments. Hikma Pharmaceuticals's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was €1 Mil.

Compared with last quarter (€1 Mil in Jun. 2023 ), Hikma Pharmaceuticals gained less money from selling investments in Dec. 2023 (€0 Mil).


Hikma Pharmaceuticals Sale Of Investment Historical Data

The historical data trend for Hikma Pharmaceuticals's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Sale Of Investment Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.60 1.64 5.31 - 0.92

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 - - 0.92 -

Hikma Pharmaceuticals Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines